Inflammatory responses and inflammation-associated diseases in organs

Oncotarget

Volumn 9, Issue 6, 2018, Pages 7204-7218

  Chen, Linlin ^a   Deng, Huidan ^a   Cui, Hengmin ^a   Fang, Jing ^a   Zuo, Zhicai ^a   Deng, Junliang ^a   Li, Yinglun ^a   Wang, Xun ^a   Zhao, Ling ^a  

^a SICHUAN AGRICULTURAL UNIVERSITY   (China)

Author keywords

Chemokines; Cytokines; Inflammation; Inflammatory signaling pathways; Organ diseases

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; STAT PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR;

BRAIN DISEASE; CELL ACTIVATION; DISEASE ASSOCIATION; ENTEROPATHY; HEART DISEASE; HUMAN; INFLAMMATION; INFLAMMATORY CELL; KIDNEY DISEASE; LIVER DISEASE; LUNG DISEASE; MOLECULAR RECOGNITION; PANCREAS DISEASE; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TISSUE INJURY;

EID: 85040931887     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.23208     Document Type: Review

References (164)

1. Medzhitov R. Inflammation 2010: new adventures of an old flame. Cell. 2010; 140:771-776
2. Ferrero-Miliani L, Nielsen O, Andersen P, Girardin S. Chronic inflammation: importance of NOD2 and NALP3 in interleukin-1β generation. Clin Exp Immunol. 2007; 147:227-235
3. Nathan C, Ding A. Nonresolving inflammation. Cell. 2010; 140:871-882
4. Zhou Y, Hong Y, Huang H. Triptolide Attenuates Inflammatory Response in Membranous Glomerulo-Nephritis Rat via Downregulation of NF-κB Signaling Pathway. Kidney and Blood Pressure Res. 2016; 41:901-910
5. Takeuchi O, Akira S. Pattern Recognition Receptors and Inflammation. Cell. 2010; 140:805-820
6. Chertov O, Yang D, Howard O, Oppenheim JJ. Leukocyte granule proteins mobilize innate host defenses and adaptive immune responses. Immunol Rev. 2000; 177:68-78
7. Jabbour HN, Sales KJ, Catalano RD, Norman JE. Inflammatory pathways in female reproductive health and disease. Reprod. 2009; 138:903-919
8. Lawrence T. The Nuclear Factor NF-κB Pathway in Inflammation. CSH Perspect Biol. 2009; dio: 10.1101/ cshperspect.a001651
9. Libby P. Inflammatory mechanisms: the molecular basis of inflammation and disease. Nutr Rev. 2007; 65:S140-S146
10. Brusselle G, Bracke K. Targeting immune pathways for therapy in asthma and chronic obstructive pulmonary disease. Annals American Thoracic Society. 2014; 11:S322-S328
11. Gudkov AV, Komarova EA. p53 and the Carcinogenicity of Chronic Inflammation. CSH Perspect Med. 2016; https:// doi.org/10.1101/cshperspect.a026161
12. Seong SY, Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol. 2004; 4:469-478
13. Ozinsky A, Underhill DM, Fontenot JD, Hajjar AM, Smith KD, Wilson CB, Schroeder L, Aderem A. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. P Natl Acad Sci. 2000; 97:13766-13771
14. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu rev of immunol. 2002; 20:197-216
15. Yamamoto M, Takeda K. Current Views of Toll-Like Receptor Signaling Pathways. Gastroenterol Res Pract. 2010: https://doi.org/10.1155/2010/240365
16. Czerkies M, Kwiatkowska K. Toll-Like Receptors and their Contribution to Innate Immunity: Focus on TLR4 Activation by Lipopolysaccharide. Adv Cell Biol. 2014; 4:1-23
17. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001; 2:675-680
18. Adib-Conquy M, Cavaillon JM. Stress molecules in sepsis and systemic inflammatory response syndrome. FEBS let. 2007; 581:3723-3733
19. Rubartelli A, Lotze MT. Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends immunol. 2007; 28:429-436
20. Kaminska B. MAPK signalling pathways as molecular targets for anti-inflammatory therapy-from molecular mechanisms to therapeutic benefits.BBA. 2005; 1754:253-262
21. Hendrayani SF, Al-Harbi B, Al-Ansari MM, Silva G, Aboussekhra A. The inflammatory/cancer-related IL-6/ STAT3/NF-κB positive feedback loop includes AUF1 and maintains the active state of breast myofibroblasts. Oncotarget. 2016; 7:41974-41985. https://doi.org/10.18632/ oncotarget.9633
22. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001; 81:807-869
23. Henríquez-Olguín C, Altamirano F, Valladares D, López JR, Allen PD, Jaimovich E. Altered ROS production, NF-κB activation and interleukin-6 gene expression induced by electrical stimulation in dystrophic mdx skeletal muscle cells. BBA-Mol Basis Disc. 2015; 1852:1410-1419
24. Girard S, Kadhim H, Roy M, Lavoie K, Brochu ME, Larouche A, Sébire G. Role of perinatal inflammation in cerebral palsy. Pediatr neurol. 2009; 40:168-174
25. Moynagh PN. The NF-kB pathway. J Cell Sci. 2005; 118:4585-4592
26. Hoffmann A, Natoli G, Ghosh G. Transcriptional regulation via the NF-|[kappa]|B signaling module. Oncogene. 2006; 25:6706-6716
27. Pasparakis M, Luedde T, Schmidt-Supprian M. Dissection of the NF-κB signalling cascade in transgenic and knockout mice. Cell Death Differ. 2006; 13:861-872
28. Basak S, Kim H, Kearns JD, Tergaonkar V, O'Dea E, Werner SL, Benedict CA, Ware CF, Ghosh G, Verma IM. A fourth IκB protein within the NF-κB signaling module. Cell. 2007; 128:369-381
29. Kadhim H, Tabarki B, Verellen G, De Prez C, Rona AM, Sebire G. Inflammatory cytokines in the pathogenesis of periventricular leukomalacia. Neurology. 2001; 56:1278-1284
30. Hayden MS, Ghosh S. NF-κB, the first quarter-century: remarkable progress and outstanding questions. Gene Dev. 2012; 26:203-234
31. Kaminska B. MAPK signalling pathways as molecular targets for anti-inflammatory therapy-from molecular mechanisms to therapeutic benefits. Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics. 2005; 1754:253-262
32. Pearson G, Robinson F, Beers GT, Xu BE, Karandikar M, Berman K, Cobb MH. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev. 2001; 22:153-183
33. Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. BBA-Mol Basis. 2010; 1802:396-405
34. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene. 2007; 26:3279-3290
35. Sabio G, Davis RJ. TNF, MAP kinase signalling pathways. Semin in Immunol. 2014; 26:237-245
36. Raingeaud J, Whitmarsh AJ, Barrett T, Dérijard B, Davis RJ. MKK3-and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Mol Cell Biolog. 1996; 16:1247-1255
37. O'Shea JJ, Schwartz DM, Villarino AV, Gadina M, Mcinnes IB, Laurence A. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015; 66:311-328
38. Walker JG, Smith MD. The Jak-STAT pathway in rheumatoid arthritis. J Rheumatol. 2005; 32:1650-1653
39. Ivashkiv LB, Hu X. The JAK/STAT pathway in rheumatoid arthritis: pathogenic or protective? Arthritis Rheumatol. 2003; 48:2092-2096
40. Boengler K, Hilfiker-Kleiner D, Drexler H, Heusch G, Schulz R. The myocardial JAK/STAT pathway: from protection to failure. Pharmacol Therapeut. 2008; 120:172-185
41. Oeckinghaus A, Hayden MS, Ghosh S. Crosstalk in NF-κB signaling pathways. Nat Immunol. 2011; 12:695-708
42. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol. 2004; 5:987-995
43. Opitz B, Van LV, Eitel J, Suttorp N. Innate immune recognition in infectious and noninfectious diseases of the lung. American J Resp Crit Care Med. 2010; 181:1294-1309
44. Rahman I, Adcock IM. Oxidative stress and redox regulation of lung inflammation in COPD. Eur Respir J. 2006; 28:219-242
45. Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, Rubin SM, Ding J, Simonsick EM, Harris TB. Inflammatory markers and onset of cardiovascular events. Circulation. 2003;108: 2317-2322
46. Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax. 2000; 55:114-120
47. Pecoits-Filho R, Heimbürger O, Bárány P, Suliman M, Fehrman-Ekholm I, Lindholm B, Stenvinkel P. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis. 2003; 41:1212-1218
48. Ross AC. Relationship between Inflammatory Markers, Endothelial Activation Markers, and Carotid Intima-Media Thickness in HIV-Infected Patients Receiving Antiretroviral Therapy. Cli Infect Dis. 2009; 49:1119-1127
49. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, Curhan GC, Rifai N, Cannuscio CC, Stampfer MJ. Inflammatory markers and the risk of coronary heart disease in men and women. New Engl J Med. 2004; 351:2599-2610
50. Bautista LE, Vera LM, Arenas IA, Gamarra G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens. 2005; 19:149-154
51. Carrero JJ, Yilmaz MI, Lindholm B, Stenvinkel P. Cytokine Dysregulation in Chronic Kidney Disease: How Can We Treat It? Blood Purificat. 2008; 26:291-299
52. Machowska A, Carrero JJ, Lindholm B, Stenvinkel P. Therapeutics targeting persistent inflammation in chronic kidney disease. Translat Res J La Clin Med. 2016; 167:204-213
53. Goldstein BI, Kemp DE, Soczynska JK, Mcintyre RS. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psych. 2009; 70:1078-1090
54. Miller AH, Maletic V, Raison CL. Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression. Biol Psych. 2009; 65:732-741
55. Lindahl B, Toss H, Siegbahn A, Venge P Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. New Engl J Med. 2000; 343:1139-1147
56. Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, Furberg CD, Psaty BM. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation. 2003; 107: 87-92
57. Gupta J, Mitra N, Kanetsky PA, Devaney J, Wing MR, Reilly M, Shah VO, Balakrishnan VS, Guzman NJ, Girndt M. Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clin J Am Soc Nephrolog Cjasn. 2012; 7:1938-1946
58. Turner MD, Nedjai B, Hurst T, Pennington DJ. Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease. BBA-Mol Cell Res.2014; 1843:2563-2582
59. Albert and Czaja. Hepatic inflammation and progressive liver fibrosis in chronic liver disease. World J Gastroenter. 2014; 20:2515-2532
60. Liu Z, Wang Y, Wang Y, Ning Q, Zhang Y, Gong C, Zhao W, Jing G, Wang Q. Dexmedetomidine attenuates inflammatory reaction in the lung tissues of septic mice by activating cholinergic anti-inflammatory pathway. Int Immunopharmacol. 2016; 35:210-216
61. Eckersall PD, Bell R. Acute phase proteins: Biomarkers of infection and inflammation in veterinary medicine. Vet J. 2010; 185:23-27
62. Murata H, Shimada N, Yoshioka M. Current research on acute phase proteins in veterinary diagnosis: an overview. Vet J. 2004; 168:28-40
63. Murakami A, Ohigashi H. Targeting NOX, INOS, COX-2 in inflammatory cells: chemoprevention using food phytochemicals. Int J Cancer. 2007; 121:2357-2363
64. Lopresti AL, Maker GL, Hood SD, Drummond PD. A review of peripheral biomarkers in major depression: the potential of inflammatory and oxidative stress biomarkers. Prog neuro-psychoph. 2014; 48:102-111
65. Huang W, Tang Y, Li L. HMGB1, a potent proinflammatory cytokine in sepsis. Cytokine. 2010; 51:119-126
66. Schierbeck H, Lundbäck P, Palmblad K, Klevenvall L, Erlandssonharris H, Andersson U, Ottosson L. Monoclonal anti-HMGB1 (high mobility group box chromosomal protein 1) antibody protection in two experimental arthritis models. Mol Med. 2011; 17:1039-1044
67. Cheng Y, Wang D, Wang B, Li H, Xiong J, Xu S, Chen Q, Tao K, Yang X, Zhu Y. HMGB1 translocation and release mediate cigarette smoke-induced pulmonary inflammation in mice through a TLR4/MyD88-dependent signaling pathway. Mol Biol Cell. 2017; 28:201-209
68. Asavarut P, Zhao H, Gu J, Ma D. The role of HMGB1 in inflammation-mediated organ injury. Acta Anaesthesiol Taiwanica. 2013; 51:28-33
69. Park J, Min JS, Kim B, Chae UB, Yun JW, Choi MS, Kong IK, Chang KT, Lee DS. Mitochondrial ROS govern the LPS-induced pro-inflammatory response in microglia cells by regulating MAPK, NF-κB pathways. Neurosci Lett. 2015; 584:191-196
70. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radical Biol Med. 2010; 49:1603-1616
71. Stramer BM, Mori R, Martin P. The inflammation-fibrosis link? A Jekyll and Hyde role for blood cells during wound repair. J Invest Dermatol. 2007; 127:1009-1017
72. Van LS, Miteva K, Tschöpe C. Crosstalk between fibroblasts and inflammatory cells. Cardiovasc Res. 2014; 102:258-269
73. Robb CT, Regan KH, Dorward DA, Rossi AG. Key mechanisms governing resolution of lung inflammation. Semin Immunopathol. 2016; 38:425-448
74. Nathan C. Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol. 2006; 6:173-182
75. Fujiwara N, Kobayashi K. Macrophages in inflammation. Current Drug Targets Inflam Allergy. 2005; 4:281-286
76. Huang C, Šali A, Stevens RL. Regulation and Function of Mast Cell Proteases in Inflammation. J Clin Immunol. 1998; 18:169-183
77. Aggrey AA, Srivastava K, Ture S, Field DJ, Morrell CN. Platelet induction of the acute-phase response is protective in murine experimental cerebral malaria. J Immunol. 2013; 190:4685-4691
78. Headland SE, Norling LV. The resolution of inflammation: Principles and challenges. Semin Immunol. 2015; 27:149-160
79. Reville K, Crean JK, Vivers S, Dransfield I, Godson C. Lipoxin A4 redistributes myosin IIA, Cdc42 in macrophages: implications for phagocytosis of apoptotic leukocytes. Jof Immunol. 2006; 176:1878-1888
80. Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol. 2005; 6:1191-1197
81. Lintermans LL, Stegeman CA, Heeringa P, Abdulahad WH. T cells in vascular inflammatory diseases. Front Immunol. 2014; 5:504
82. Sugimoto MA, Sousa LP, Pinho V, Perretti M, Teixeira MM. Resolution of Inflammation: What Controls Its Onset? Front Immuno. 2016; https://doi.org/10.3389/ fimmu.2016.00.00160
83. He G, Karin M. NF-κB, STAT3-key players in liver inflammation and cancer. Cell Res. 2011; 21:159-168
84. Sofi F, Fabbri A, Casini A. Inflammation and Cardiovascular Disease and Protection by the Mediterranean Diet. Mediterranean Diet: Springer International publishing.2016; 89-96
85. Khan N, Khymenets O, Urpísardà M, Tulipani S, Garciaaloy M, Monagas M, Moracubillos X, Llorach R, Andreslacueva C. Cocoa Polyphenols and Inflammatory Markers of Cardiovascular Disease. Nutrients. 2014; 6:844-880
86. Lloydjones D, Adams RJ, Brown TM, Carnethon M, Dai S, Simone GD, Ferguson TB, Ford E, Furie K, Gillespie C. Heart Disease and Stroke Statistics-2010 Update A Report From the American Heart Association. Circulation. 2010; 115:e25-e146
87. Mathers CD, Loncar D. Projections of Global Mortality and Burden of Disease from 2002 to 2030. Plos Med. 2006; 3:e442
88. Packard RRS, Peter L. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem. 2008; 54:24-38
89. Libby P. History of Discovery: Inflammation in Atherosclerosis. Arteriosclerosis Thrombosis Vascular Biology. 2012; 32:2045-2051
90. Libby P. Atherosclerosis in Inflammation. Nature. 2002; 420:868-874
91. Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation in atherosclerosis: transition from theory to practice. Circulation J. 2010; 74:213-220
92. Glezeva N, Baugh JA. Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target. Heart Fail Rev. 2014; 19:681-694
93. Askevold ET, Gullestad L, Dahl CP, Yndestad A, Ueland T, Aukrust P. Interleukin-6 signaling, soluble glycoprotein 130, and inflammation in heart failure. Curr Heart Fail Reports. 2014; 11:146-155
94. Jennings RB, Murry CE, Steenbergen C Jr, Reimer KA. Development of cell injury in sustained acute ischemia. Circulation. 1990; 82:II2-12
95. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 1990; 81:1161-1172
96. Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA. Controversies in ventricular remodelling. Lancet. 2006; 367:356-367
97. Frangogiannis NG. The immune system and cardiac repair. Pharmacol Res. 2008; 58:88-111
98. Beg AA. Endogenous ligands of Toll-like receptors: implications for regulating inflammatory and immune responses. Trends Immunol. 2002; 23:509-512
99. Frantz S, Ertl G, Bauersachs J. Mechanisms of Disease: Toll-like receptors in cardiovascular disease. Nat Clin Pract Card. 2007; 4:444-454
100. Nijmeijer R, Lagrand WK, Visser CA, Meijer CJ, Niessen HW, Hack CE. CRP, a major culprit in complementmediated tissue damage in acute myocardial infarction? Int Immunopharmacol. 2001; 1:403-414
101. Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest. 2005; 115:500-508
102. Griendling KK, Fitzgerald GA. Oxidative Stress and Cardiovascular Injury: Part I: Basic Mechanisms and In Vivo Monitoring of ROS. Circulation. 2003; 108:1912-1916
103. Hall G, Hasday JD, Rogers TB. Regulating the regulator: NF-κB signaling in heart. J Mol Cell Cardiol. 2006; 41:580-591
104. Gerard C, Rollins BJ. Chemokines and disease. Nat Immunol. 2001; 2:108-115
105. Moser B, Loetscher P. Lymphocyte traffic control by chemokines. Nat Immunol. 2001; 2:123-128
106. Kaur K, Dhingra S, Slezak J, Sharma AK, Bajaj A, Singal PK. Biology of TNFa and IL-10, and their imbalance in heart failure. Heart Fail Rev. 2009; 14:113-123
107. Frangogiannis NG. Targeting the transforming growth factor (TGF)-β cascade in the remodeling heart: Benefits and perils. J Mol Cell Cardiol. 2014; 76:169-171
108. Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a populationbased retrospective cohort study. Lancet. 2006; 368:29-36
109. Low Wang CC, Hess CN, Hiatt WR, Goldfine AB. Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus-Mechanisms, Management, and Clinical Considerations. Circulation. 2016; 133:2459-2502
110. Turner MD. The identification of TNFR5 as a therapeutic target in diabetes. Taylor Francis. 2017; 21:349-351
111. Pradeep T, Haranath C. A Review on Diabetes Mellitus Type II. Int J Pharma Res Rev. 2014; 3:23-29
112. Larsen CM, Faulenbach M, Vaag A, Vølund A, Ehses JA, Seifert B, Mandrup-Poulsen T, Donath MY. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. New Engl J Med . 2007; 356 :1517-1526
113. Donath MY, Schumann DM, Faulenbach M, Ellingsgaard H, Perren A, Ehses JA. Islet inflammation in type 2 diabetes. Diabetes care. 2008; 31:S161-S164
114. Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pr. 2014; 105:141-150
115. Dinarello CA, Donath MY, Mandrup-Poulsen T. Role of IL-1β in type 2 diabetes. Curr Opin Endocrinol. 2010; 17:314-321
116. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011; 11:98-107
117. Manohar M, Verma AK, Venkateshaiah SU, Sanders NL, Mishra A. Pathogenic mechanisms of pancreatitis. World J Gastr Pharmacol Therapeut. 2017; 8:10-25
118. Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology. 2013; 144:1252-1261
119. Zheng L, Xue J, Jaffee EM, Habtezion A. Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma. Gastroenterology. 2013; 144:1230-1240
120. Zhang H, Neuhöfer P, Song L, Rabe B, Lesina M, Kurkowski MU, Treiber M, Wartmann T, Regnér S, Thorlacius H. IL-6 trans-signaling promotes pancreatitisassociated lung injury and lethality. J Clin Invest. 2013; 123:1019-1031
121. Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015; 518:495-501
122. Ling S, Feng T, Jia K, Tian YU, Yan LI. Inflammation to cancer: The molecular biology in the pancreas (Review). Oncol Lett. 2014; 7:1747-1754
123. Whitcomb DC. Inflammation and Cancer V. Chronic pancreatitis and pancreatic cancer. Am J Physiol-Gastr L. 2004; 287:G315-G319
124. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004; 363:1049-1057
125. Goggins M, Hruban RH, Kern SE. BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications. Am J pathoL. 2000; 156:1767-1771
126. Shi Q, Le X, Wang B, Abbruzzese JL, Xiong Q, He Y, Xie K. Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells. Oncogene. 2001; 20:3751-3756
127. Xie K. Interleukin-8 and human cancer biology. Cytokine Growth F R. 2001; 12:375-391
128. Brenner C, Galluzzi L, Kepp O, Kroemer G. Decoding cell death signals in liver inflammation. J Hepatol. 2013; 59:583-594
129. Leitão HS, Doblas S, Garteiser P, D'Assignies G, Paradis V, Mouri F, Geraldes CF, Ronot M, Van Beers BE. Hepatic Fibrosis, Inflammation, and Steatosis: Influence on the MR Viscoelastic and Diffusion Parameters in Patients with Chronic Liver Disease. Radiology. 2016: 283:98-1107
130. Ramadori G, Moriconi F, Malik I, Dudas J. Physiology and pathophysiology of liver inflammation, damage and repair. J Physiol Pharmacol. 2008; 59:107-117
131. Pawlotsky JM. Pathophysiology of hepatitis C virus infection and related liver disease. Trends in Microbiol. 2004; 12:96-102
132. Dunn C, Brunetto M, Reynolds G, Christophides T, Kennedy PT, Lampertico P, Das A, Lopes AR, Borrow P, Williams K, Humphreys E, Afford S, Adams DH, et al. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med. 2007; 204:667-680
133. Gao B, Seki E, Brenner DA, Friedman S, Cohen JI, Nagy L, Szabo G, Zakhari S. Innate immunity in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol. 2011; 300:516-525
134. Brenner DA, Seki E, Taura K, Kisseleva T, Deminicis S, Iwaisako K, Inokuchi S, Schnabl B, Oesterreicher CH, Yong HP. Non-alcoholic steatohepatitis-induced fibrosis: Tolllike receptors, reactive oxygen species and Jun N-terminal kinase. Hepatol Res. 2011; 41:683-686
135. Maher JJ. DAMPs ramp up drug toxicity. J Clin Invest. 2009; 119:246-249
136. Kubes P, Mehal WZ. Sterile Inflammation in the Liver. Gastroenterology. 2012; 143:1158-1172
137. Poltorak A, He X, Smirnova I, Liu MY, Huffel CV, Du X, Birdwell D, Alejos E, Silva M, Galanos C. Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 Gene. science. 1998; 282:2085-2088
138. Szabo G, Mandrekar P, Dolganiuc A. Innate immune response and hepatic inflammation. Seminars in Liver Disease. 2007; 27:339-350
139. Walford HH, Doherty TA. STAT6 and lung inflammation. Jakstat. 2013; 2:e25301-e25311
140. Leitch AE, Duffin R, Haslett C, Rossi AG. Relevance of granulocyte apoptosis to resolution of inflammation at the respiratory mucosa. Mucosal Immunol. 2008; 1:350-363
141. Brusselle G, Bracke K. Targeting immune pathways for therapy in asthma and chronic obstructive pulmonary disease. Annals of the American Thoracic Society. 2014; 11:329-335
142. Wong J, Magun BE, Wood LJ. Lung inflammation caused by inhaled toxicants: a review. Int J of Copd. 2016; 11:1391-1401
143. Mroz RM, Noparlik J, Chyczewska E, Braszko JJ, Holownia A. Molecular basis of chronic inflammation in lung diseases: new therapeutic approach. J Physiol Pharmacol. 2007; 58:453-460
144. Kawayama T, Kinoshita T, Matsunaga K, Kobayashi A, Hayamizu T, Johnson M, Hoshino T. Responsiveness of blood and sputum inflammatory cells in Japanese COPD patients, non-COPD smoking controls, and non-COPD nonsmoking controls. Int J Copd. 2016; 11:295-303
145. Ernandez T, Mayadas TN. The Changing Landscape of Renal Inflammation. Trends Mol Med. 2016; 22:151-163
146. Poveda J, Sanz AB, Rayegomateos S, Ruizortega M, Carrasco S, Ortiz A, Sanchezniño MD. NFκBiz protein downregulation in acute kidney injury: Modulation of inflammation and survival in tubular cells. BBA-Mol Basis Dis. 2016; 1862:635-646
147. Sanz A, Sanchez-Niño M, Ramos A, Moreno J, Santamaria B, Ruiz-Ortega M, Egido J, Ortiz A. NF-kappaB in renal inflammation. J Am Soc Nephrol. 2010; 21:1254-1262
148. Chawla LS, Kimmel PL. Acute kidney injury and chronic kidney disease: an integrated clinical syndrome. Kidney Int. 2012; 82:516-524
149. Sanchez MIP, Bercik P. Epidemiology and burden of chronic constipation. Can J Gastroenterol 2011; 25:11B-15B
150. Hunt R, Quigley E, Abbas Z, Eliakim A, Emmanuel A, Goh KL, Guarner F, Katelaris P, Smout A, Umar M. Coping with common gastrointestinal symptoms in the community: a global perspective on heartburn, constipation, bloating, and abdominal pain/discomfort May 2013. J Clin Gastroenterol. 2014; 48:567-578
151. Mcguckin MA, Eri R, Simms LA, Florin TH, Radford-Smith G. Intestinal barrier dysfunction in inflammatory bowel diseases. Inflamm Bowel Dis. 2009; 15:100-113
152. Cario E, Podolsky DK. Differential Alteration in Intestinal Epithelial Cell Expression of Toll-Like Receptor 3 (TLR3) and TLR4 in Inflammatory Bowel Disease. Infection Immunity. 2000; 68:7010-7017
153. Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest. 2007; 117:514-521
154. Fukata M, Arditi M. The role of pattern recognition receptors in intestinal inflammation. Mucosal Immunol. 2013; 6:451-463
155. Thompson MR, Kaminski JJ, Kurt-Jones EA, Fitzgerald KA. Pattern Recognition Receptors and the Innate Immune Response to Viral Infection. Viruses. 2011; 3:920-940
156. Goswami B, Rajappa M, Sharma M, Sharma A. Inflammation: its role and interplay in the development of cancer, with special focus on gynecological malignancies. Int J Gynecol Cancer. 2008; 18:591-599
157. Levi M, van der Poll T. Two-way interactions between inflammation and coagulation. Trends Cardiovascular Med. 2005; 15:254-259
158. Sampson MT, Kakkar AK. Coagulation proteases and human cancer. Biochem Soc T. 2002; 30:201-207
159. Nelson PT, Soma LA, Lavi E. Microglia in diseases of the central nervous system. Annals Med. 2002; 34:491-500
160. Vezzani A, Granata T. Brain Inflammation in Epilepsy: Experimental and Clinical Evidence. Epilepsia. 2005; 46:1724-1743
161. Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neuro. 2007; 8:57-69
162. Ekdahl CT, Claasen JH, Bonde S, Kokaia Z, Lindvall O. Inflammation is detrimental for neurogenesis in adult brain. P Natl Acad of Sci USA. 2003; 100:13632-13637
163. Koltsakis GC, Stamatelos AM. Cytokines and acute neurodegeneration. Nat Rev Neuro. 2001; 2:734-744
164. Jankowsky JL, Patterson PH. The role of cytokines and growth factors in seizures and their sequelae. Prog Neurobio. 2001; 63:125-149